Abstract
Oridonin, an ent-kaurane diterpenoid mainly extracted from Chinese medical plant Rabdosia rubescens and some related species, has been reported its remarkable antitumor efficacy in various cancer cells. This review will be focused on the underlying molecular mechanisms for the treatments of oridonin in hematological malignancies, which include the regulation of oncoproteins (AML1-ETO, NPM1 mutants, PML-RARα, ABL kinase), accumulation of ROS, modulation of MAPKs and PI3K/Akt signaling pathways, and changes of abnormal expressions of MicroRNAs. And we get the conclusion that oridonin is a promising natural product with multiple targets against hematological malignancies.
Keywords: Oridonin, molecular mechanism, antitumor, hematological malignancies.
Current Pharmaceutical Biotechnology
Title:Oridonin, a Promising Antitumor Natural Product in the Chemotherapy of Hematological Malignancies
Volume: 15 Issue: 11
Author(s): Zichu Zhao and Yan Chen
Affiliation:
Keywords: Oridonin, molecular mechanism, antitumor, hematological malignancies.
Abstract: Oridonin, an ent-kaurane diterpenoid mainly extracted from Chinese medical plant Rabdosia rubescens and some related species, has been reported its remarkable antitumor efficacy in various cancer cells. This review will be focused on the underlying molecular mechanisms for the treatments of oridonin in hematological malignancies, which include the regulation of oncoproteins (AML1-ETO, NPM1 mutants, PML-RARα, ABL kinase), accumulation of ROS, modulation of MAPKs and PI3K/Akt signaling pathways, and changes of abnormal expressions of MicroRNAs. And we get the conclusion that oridonin is a promising natural product with multiple targets against hematological malignancies.
Export Options
About this article
Cite this article as:
Zhao Zichu and Chen Yan, Oridonin, a Promising Antitumor Natural Product in the Chemotherapy of Hematological Malignancies, Current Pharmaceutical Biotechnology 2014; 15 (11) . https://dx.doi.org/10.2174/1389201015666141111115608
DOI https://dx.doi.org/10.2174/1389201015666141111115608 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Hedgehog Signaling in the Normal and Neoplastic Mammary Gland
Current Drug Targets Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy
Current Gene Therapy Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design Significance of CD34 Negative Hematopoietic Stem Cells and CD34 Positive Mesenchymal Stem Cells – A Valuable Dimension to the Current Understanding
Current Stem Cell Research & Therapy Genes Involved in Hereditary Hearing Impairment
Current Genomics Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology Editorial (Another Year of Prosperity for Current Molecular Medicine)
Current Molecular Medicine Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Current Drug Targets Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Topical Therapy for Actinic Keratoses: Current and Evolving Therapies
Reviews on Recent Clinical Trials Role of Alterations in the Apoptotic Machinery in Sensitivity of Cancer Cells to Treatment
Current Pharmaceutical Design Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology Kinases as Drug Discovery Targets in Hematologic Malignancies
Current Molecular Medicine